Neoadjuvant therapy for ER-positive breast cancers

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Colleoni, M ^a   Montagna, E ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Luminal subtype; Neoadjuvant

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; GEMCITABINE; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84866762948     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds305     Document Type: Article

References (50)

1. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
2. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
3. Kuerer HM, Newman LA, Smith TM et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
4. Kaufmann M, von Minckwitz G, Mamounas EP et al. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Ann Surg Oncol 2011; epub ahead of print 23 December.
5. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
6. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
7. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
8. Colleoni M, Bagnardi V, Rotmensz N et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2009; 116: 359-369.
9. Petit T, Wilt M, Velten M et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40(2): 205-211.
10. Dowsett M, Smith IE, Ebbs SR et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005; 11:951s-958s.
11. Colleoni M, Bagnardi V, Rotmensz N et al. A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. Eur J Cancer 2010; 46(12): 2216-2224.
12. Jones RL, Salter J, A'Hern R et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116(1): 53-68.
13. Colleoni M, Bagnardi V, Rotmensz N et al. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol 2009; 20: 1178-1184.
14. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-170.
15. Ellis MJ, Tao Y, Luo J et al. Outcome prediction for estrogen receptor-positive breast cancer based on post neoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100: 1380-1388.
16. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
17. Dowsett M, Nielsen TO, A'Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103: 1656-1664.
18. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffinembedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-7277.
19. Ellis ME, Suman VJ, Hoog J et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausale women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011; 29: 2342-2349.
20. Liedtke C, Hatzis C, Symmans WF et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009, 27: 3185-3191.
21. Hatzis C, Pusztai L, Valero V et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011; 305: 1873-1881.
22. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 8: 1736-1747.
23. Abrial C, Mouret-Reynier M-A, Curé H et al. Neoadjuvant endocrine therapy in breast cancer. Breast 2006; 15: 9-19.
24. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19: 881-894.
25. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
26. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-518.
27. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527-1532.
28. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63: 6523-6531.
29. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative 'Arimidex' Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106: 2095-2103.
30. Seo JH, Kim YH, Kim JS et al. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer. Cancer Chemother Pharmacol 2009; 63: 261-266.
31. Semiglazov V, Kletsel A, Semiglazov V et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). J Clin Oncol 2005; 23:16S (Abstract 530).
32. Dixon JM, Renshaw L, Macaskill EJ et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 2009; 113: 145-151.
33. Miller WR. Aromatase inhibitors: prediction of response and nature of resistance. Expert Opin Pharmacother 2010; 11: 1873-1887.
34. Crowder RJ, Phommaly C, Tao Y et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptorpositive breast cancer. Cancer Res 2009; 6: 3955-3962.
35. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2630-2637.
36. Gazet JC, Ford HT, Gray R et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 2001; 12: 685-691.
37. Torrisi R, Bagnardi V, Pruneri G et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 2007; 97: 802-808.
38. Masuda N, Sagara Y, Kinoshita T et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 2012; epub ahead of print 19 January.
39. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
40. von Minckwitz G, Untch M, Nüesch E et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-156.
41. Osborne CK. Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer. In Jordan VC (ed.), Long Term Tamoxifen for Breast Cancer. Madison, WI: The University of Wisconsin Press 1994; 181-198.
42. Pico C, Martin M, Jara C et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 2004; 15: 79-87.
43. Kaufmann M, von Minckwitz G, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18: 1927-1934.
44. Bottini A, Generali D, Brizzi MP et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006; 24: 3623-3628.
45. Torrisi R, Bagnardi V, Rotmensz N et al. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Res Treat 2011; 126: 431-441.
46. Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-320.
47. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
48. Colleoni M, Russo L, Dellapasqua S. Adjuvant therapies for special types of breast cancer. Breast 2011; 20(Suppl. 3): S153-S157.
49. Page DL. Special types of invasive breast cancer, with clinical implications. Am J Surg Pathol 2003; 27: 832-835.
50. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23: 41-418.